This site is intended for healthcare professionals

Tirzepatide significantly reduced A1C and body weight in type 2 diabetes in two phase III trials from the SURPASS program.- Eli Lilly

Read time: 4 mins
Last updated:19th Feb 2021
Published:19th Feb 2021
Condition: Obesity and Diabetes
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest